LeMaitre Vascular, Inc. $LMAT Shares Acquired by Congress Asset Management Co.

Congress Asset Management Co. boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 5.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 732,331 shares of the medical instruments supplier’s stock after acquiring an additional 40,065 shares during the quarter. Congress Asset Management Co. owned 3.23% of LeMaitre Vascular worth $59,392,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. First Trust Advisors LP raised its holdings in shares of LeMaitre Vascular by 35.4% during the third quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock valued at $72,541,000 after acquiring an additional 216,919 shares during the last quarter. Millennium Management LLC boosted its stake in shares of LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after acquiring an additional 115,141 shares during the last quarter. Grandeur Peak Global Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the second quarter worth approximately $6,275,000. Tudor Investment Corp ET AL purchased a new stake in shares of LeMaitre Vascular during the third quarter worth approximately $6,056,000. Finally, Goldman Sachs Group Inc. raised its stake in LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after purchasing an additional 55,804 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 1.5%

NASDAQ:LMAT opened at $107.86 on Tuesday. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $115.33. The stock’s fifty day moving average is $95.05 and its two-hundred day moving average is $89.71. The stock has a market capitalization of $2.46 billion, a price-to-earnings ratio of 42.97, a price-to-earnings-growth ratio of 3.06 and a beta of 0.66. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm had revenue of $64.45 million for the quarter, compared to analyst estimates of $62.98 million. During the same quarter in the prior year, the company earned $0.49 EPS. LeMaitre Vascular’s revenue was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, March 12th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 39.84%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LMAT shares. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Roth Mkm reissued a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Wells Fargo & Company boosted their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. Citizens Jmp upped their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research report on Thursday, February 26th. Finally, Barrington Research increased their price target on LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $105.80.

Insider Activity

In other LeMaitre Vascular news, Director David B. Roberts sold 8,464 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the transaction, the director directly owned 17,979 shares in the company, valued at $1,920,157.20. This represents a 32.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 150,000 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the completion of the transaction, the chief executive officer owned 1,532,304 shares in the company, valued at $163,588,775.04. This represents a 8.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 215,438 shares of company stock worth $23,062,911. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.